肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能

2018-04-27 MedSci MedSci原创

BRAFHSP90黑色素瘤耐药性
关注

科学家们尝试将药物联合起来，以预防导致黑色素瘤患者癌症再生的抗性的发展。由于过去十年已批准的几种新疗法，如BRAF和MEK抑制剂，晚期或转移性黑素瘤患者能够延长无疾病进展生存期。然而，尽管这些靶向药物取得了部分成功，但大多数患者最终会产生耐药性，导致癌症再生。

科学家们尝试将药物联合起来，以预防导致黑色素瘤患者癌症再生的抗性的发展。由于过去十年已批准的几种新疗法，如BRAF和MEK抑制剂，晚期或转移性黑素瘤患者能够延长无疾病进展生存期。然而，尽管这些靶向药物取得了部分成功，但大多数患者最终会产生耐药性，导致癌症再生。Moffitt癌症中心的一个研究小组一直在研究黑色素瘤细胞如何对BRAF抑制剂产生抗药性以开发新的治疗策略。他们测试了一种靶向热休克蛋白90（HSP90）的药物与BRAF抑制剂vemurafenib联合是否是治疗黑素瘤患者的安全有效的策略。

BRAF基因编码一种蛋白质，它是细胞存活和生长的重要调节因子，因此是控制肿瘤的潜在靶点。大约50%的黑色素瘤患者在BRAF基因中存在突变。两种靶向突变BRAF（vemurafenib和达拉非尼）被批准用于治疗BRAF突变的黑色素瘤患者，这些患者不能通过手术切除治疗或已扩散至其他部位。这些药物可改善黑色素瘤患者的存活率，并经常与MEK抑制剂联合使用，然而，最终的耐药性非常普遍。

Moffitt的研究人员先前发表了一项临床前研究，显示HSP90抑制剂XL888克服了黑素瘤细胞对vemurafenib的耐药性。该团队从细胞培养和小鼠研究中获取的这些信息，并将其转化为I期临床试验，以评估XL888联合vemurafenib治疗黑色素瘤患者的最佳剂量。

原始出处：

https://www.europeanpharmaceuticalreview.com/news/75117/combining-drugs-braf-hsp90-melanoma/

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707666, encodeId=7b321e0766681, content=<a href='/topic/show?id=b7959158af' target=_blank style='color:#2F92EE;'>#HSP90#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9158, encryptionId=b7959158af, topicName=HSP90)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fd31458035, createdName=ms5906905816781247, createdTime=Sun Aug 12 07:57:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807709, encodeId=5e3a180e70987, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80732, encryptionId=865480e3299, topicName=联合靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Sep 03 04:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354988, encodeId=83e01354988de, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479421, encodeId=2d6b14e942146, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-08-12 ms5906905816781247

    #HSP90#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1707666, encodeId=7b321e0766681, content=<a href='/topic/show?id=b7959158af' target=_blank style='color:#2F92EE;'>#HSP90#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9158, encryptionId=b7959158af, topicName=HSP90)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fd31458035, createdName=ms5906905816781247, createdTime=Sun Aug 12 07:57:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807709, encodeId=5e3a180e70987, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80732, encryptionId=865480e3299, topicName=联合靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Sep 03 04:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354988, encodeId=83e01354988de, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479421, encodeId=2d6b14e942146, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-09-03 xiongliangxl

    #联合靶向#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1707666, encodeId=7b321e0766681, content=<a href='/topic/show?id=b7959158af' target=_blank style='color:#2F92EE;'>#HSP90#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9158, encryptionId=b7959158af, topicName=HSP90)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fd31458035, createdName=ms5906905816781247, createdTime=Sun Aug 12 07:57:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807709, encodeId=5e3a180e70987, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80732, encryptionId=865480e3299, topicName=联合靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Sep 03 04:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354988, encodeId=83e01354988de, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479421, encodeId=2d6b14e942146, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-04-29 zhaojie88

    #BRAF#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1707666, encodeId=7b321e0766681, content=<a href='/topic/show?id=b7959158af' target=_blank style='color:#2F92EE;'>#HSP90#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9158, encryptionId=b7959158af, topicName=HSP90)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fd31458035, createdName=ms5906905816781247, createdTime=Sun Aug 12 07:57:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807709, encodeId=5e3a180e70987, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80732, encryptionId=865480e3299, topicName=联合靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Mon Sep 03 04:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354988, encodeId=83e01354988de, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479421, encodeId=2d6b14e942146, content=<a href='/topic/show?id=4a571033209b' target=_blank style='color:#2F92EE;'>#黑素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103320, encryptionId=4a571033209b, topicName=黑素瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d4d7523220, createdName=yuhaisheng_ibp_32061713, createdTime=Sun Apr 29 13:57:00 CST 2018, time=2018-04-29, status=1, ipAttribution=)]
    2018-04-29 yuhaisheng_ibp_32061713

    #黑素瘤#

    0

相关资讯

Gastroenterology：炎性饮食与结直肠癌的分型有关

背景：我们日常的饮食模式会影响全身的炎症状况，其中也会对结肠癌的发生产生一定影响，因为慢性炎症会干扰身体的免疫应答。本项研究探讨了炎性的饮食结构与结直肠癌的发生的关系。

JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值

目前尚无研究针对原发肿瘤位置对不同BRAF，RAS和微卫星灶不稳定（MSI）状态的接受结肠癌切除并进行标准辅助化疗的患者预后的影响。JAMA Oncology近期发表了一篇文章，研究Ⅲ期结肠癌患者接受FOLFOX联合或不联合西妥昔单抗治疗后不同BRAF，RAS和MSI状态原发肿瘤位置的预后价值。

CLIN CANCER RES：PI3K和BRAF联合抑制治疗晚期BRAF V600突变实体肿瘤

PI3K/AKT/mTOR通路与许多实体肿瘤有关，且被认为是BRAF抑制耐药的机制之一。因此，对BRAF V600突变的肿瘤，PI3K抑制剂与BRAF抑制剂联合治疗成为一种可行方案。CLIN CANCER RES近期发表了一篇文章，评估口服平PX-866联合每天2次Vemurafenib的安全性以及这一治疗策略的潜在预测性标志。

全新分子MK-8353显示出对黑色素瘤的治疗希望

近日，在一项早期临床试验中，旨在阻断晚期黑色素瘤和其他肿瘤中过度活化的细胞生长信号的在研化合物显示出了良好的治疗前景。作为该项目的研究者，北卡罗来纳大学的Stergios Moschos博士及其同事公布了第一阶段的结果，在这项多中心试验中，研究者们招募了含有BRAF或RAS基因突变的黑色素瘤和其他肿瘤患者，共涉及26例患者，对患者使用新型化合物MK-8353进行治疗，该化合物旨在阻断驱动耐药性黑色

EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变

BRAF / MEK抑制剂和免疫治疗剂已经被批准用于治疗转移性BRAF突变的黑色素瘤

J NATL CANCER I：BRAFV600突变非黑色素肿瘤的共存基因改变可影响生存？

BRAF突变可发生于非黑色素肿瘤中，靶向BRAF的药物却一直未能获批治疗此类肿瘤，这主要源于BRAF抑制剂对BRAF突变非黑色素肿瘤原发或继发耐药，肿瘤中与BRAFV600突变共存的基因改变可能与耐药相关，因此美国Sen教授分析了BRAFV600突变肿瘤的共存基因改变以及改变对BRAFV600抑制剂耐药、肿瘤PFS和OS的影响，研究结果发表在JNCI。